These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 37144395)
21. Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. Ullrich S; Ekanayake KB; Otting G; Nitsche C Bioorg Med Chem Lett; 2022 Apr; 62():128629. PubMed ID: 35182772 [TBL] [Abstract][Full Text] [Related]
22. Development of a colorimetric assay for the detection of SARS-CoV-2 3CLpro activity. Garland GD; Harvey RF; Mulroney TE; Monti M; Fuller S; Haigh R; Gerber PP; Barer MR; Matheson NJ; Willis AE Biochem J; 2022 Apr; 479(8):901-920. PubMed ID: 35380004 [TBL] [Abstract][Full Text] [Related]
23. Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CL Ma L; Xie Y; Zhu M; Yi D; Zhao J; Guo S; Zhang Y; Wang J; Li Q; Wang Y; Cen S Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555652 [TBL] [Abstract][Full Text] [Related]
24. Watuguly T; Bare Y; Ratih Tirto Sari D; Kustarini Samsuria I Pak J Biol Sci; 2022 Jan; 25(9):867-874. PubMed ID: 36098090 [TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and biological evaluation of betulinic acid derivatives as potential inhibitors of 3CL-protease of SARS-CoV-2. Liu Y; Nie T; Hou J; Long H; Zhang Z; Lei M; Xu Y; Wu W Steroids; 2024 Feb; 202():109351. PubMed ID: 38101718 [TBL] [Abstract][Full Text] [Related]
26. Exploring 2-methyl-substituted vitamin K Koharazawa R; Hayakawa M; Takeda K; Miyazaki K; Tode C; Hirota Y; Suhara Y Bioorg Med Chem Lett; 2024 Mar; 100():129642. PubMed ID: 38310976 [TBL] [Abstract][Full Text] [Related]
28. Synthesis of Dihydrobenzofuro[3,2-b]chromenes as Potential 3CLpro Inhibitors of SARS-CoV-2: A Molecular Docking and Molecular Dynamics Study. Gorai S; Junghare V; Kundu K; Gharui S; Kumar M; Patro BS; Nayak SK; Hazra S; Mula S ChemMedChem; 2022 Apr; 17(8):e202100782. PubMed ID: 35112482 [TBL] [Abstract][Full Text] [Related]
29. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach. Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862 [TBL] [Abstract][Full Text] [Related]
30. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. Mody V; Ho J; Wills S; Mawri A; Lawson L; Ebert MCCJC; Fortin GM; Rayalam S; Taval S Commun Biol; 2021 Jan; 4(1):93. PubMed ID: 33473151 [TBL] [Abstract][Full Text] [Related]
31. The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease. Chiou WC; Chen JC; Chen YT; Yang JM; Hwang LH; Lyu YS; Yang HY; Huang C Biochem Biophys Res Commun; 2022 Feb; 591():130-136. PubMed ID: 33454058 [TBL] [Abstract][Full Text] [Related]
32. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy. Goyal B; Goyal D ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186 [TBL] [Abstract][Full Text] [Related]
33. Discovery of Nirmatrelvir Resistance Mutations in SARS-CoV-2 3CLpro: A Computational-Experimental Approach. Havranek B; Demissie R; Lee H; Lan S; Zhang H; Sarafianos S; Ayitou AJ; Islam SM J Chem Inf Model; 2023 Nov; 63(22):7180-7188. PubMed ID: 37947496 [TBL] [Abstract][Full Text] [Related]
34. Biochemical and biophysical characterization of the main protease, 3-chymotrypsin-like protease (3CLpro) from the novel coronavirus SARS-CoV 2. Ferreira JC; Rabeh WM Sci Rep; 2020 Dec; 10(1):22200. PubMed ID: 33335206 [TBL] [Abstract][Full Text] [Related]
35. Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL Ma L; Li Q; Xie Y; Jianyuan Zhao ; Yi D; Guo S; Guo F; Wang J; Yang L; Cen S Antiviral Res; 2022 Nov; 207():105419. PubMed ID: 36155070 [TBL] [Abstract][Full Text] [Related]
36. Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332. Li J; Lin C; Zhou X; Zhong F; Zeng P; Yang Y; Zhang Y; Yu B; Fan X; McCormick PJ; Fu R; Fu Y; Jiang H; Zhang J J Virol; 2022 Apr; 96(8):e0201321. PubMed ID: 35389231 [TBL] [Abstract][Full Text] [Related]